Navigation Links
BioLineRx to Hold Analyst and Investor Day in New York on November 21, 2013
Date:11/5/2013

JERUSALEM, Nov. 5, 2013 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX; TASE: BLRX), a biopharmaceutical development company, announced that it will host an Analyst & Investor Day on Thursday, November 21, 2013 in New York City beginning at 8:15 am EST.

(Logo:  http://photos.prnewswire.com/prnh/20130730/630769 )

The event will feature presentations from members of BioLineRx's senior management team, including a unique perspective on the current state of the biotechnology market and industry trends by recently appointed BioLineRx Director, Dr. BJ Bormann, most recently Senior Vice President and Worldwide Head of Therapeutic Alliances and Strategic Partnerships at Boehringer Ingelheim Pharmaceuticals Inc., and former Vice President, Strategic Alliances, at Pfizer.

Selected key opinion leaders will be speaking in reference to several programs within BioLineRx's pipeline, including:

  • BL-8040 (for treatment of AML and other hematological cancers) - Dr. Martin Tallman, of Sloan-Kettering Memorial Cancer Center, will provide insight on the current AML and hematological oncology space and the market for potential breakthrough products such as BL-8040
  • BL-5010 (for treatment of skin lesions) - Dr. Miri Seiberg, a world-renowned independent dermatology expert, will be providing insight on the current need for new skin lesion therapies and the relevant market potential for such therapies
  • BL-7010 (for treatment of celiac disease) - Dr. Joseph A. Murray, a leading celiac disease researcher at the Mayo Clinic, will discuss the current state of the celiac market and enormous need for breakthrough celiac treatments

The presentations will begin at 9:00 am EST and conclude at approximately 11:45 am EST. A recording of the presentations will be available after the event, through the Investor Relations section of BioLineRx's website, www.biolinerx.com, and at www.kcsa.com.

Analysts and qualified investors who would like to register or learn more about the event should contact Diane Imas of KCSA Strategic Communications at (212) 896-1242 or dimas@kcsa.com. Registration is required as space is limited.

About BioLineRx
BioLineRx is a publicly-traded biopharmaceutical development company dedicated to building a portfolio of products for unmet medical needs, as well as those with advantages over currently available therapies. The Company in-licenses novel compounds primarily from academic institutions and biotech companies based in Israel, develops them through pre-clinical and/or clinical stages, and then partners with pharmaceutical companies for advanced clinical development and/or commercialization.

BioLineRx's current portfolio consists of a variety of clinical and pre-clinical projects, including: BL-1040 for prevention of pathological cardiac remodeling following a myocardial infarction, which has been out-licensed to Ikaria Inc. and is in the midst of a pivotal CE-Mark registration trial; BL-5010 for non-surgical removal of skin lesions, which is expected to commence a pivotal CE-mark registration trial in late 2013; BL-8040 for treating acute myeloid leukemia (AML) and other hematological cancers, which is in the midst of a Phase 2 study; and BL-7010 for celiac disease, which is expected to commence a Phase 1/2 study in late 2013.

For more information on BioLineRx, please visit www.biolinerx.com or download the investor relations mobile device app, which allows users access to the Company's SEC documents, press releases, and events. BioLineRx's IR app is available on the iTunes App Store as well as the Google Play Store.

Contacts:
Garth Russell / Todd Fromer
KCSA Strategic Communications
1 212-896-1250 / 1 212-896-1215
grussell@kcsa.com / tfromer@kcsa.com

or

Tsipi Haitovsky
Public Relations
+972-52-598-9892
tsipih@netvision.net.il

 


'/>"/>
SOURCE BioLineRx Ltd.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. BioLineRx Receives Regulatory Approval to Commence Phase 1/2 Trial for Novel Treatment of Celiac Disease
2. BioLineRx Announces In-Licensing of BL-9020, for Treatment of Type 1 Diabetes
3. BioLineRx Announces Regulatory Submission for Phase 1/2 Trial for Novel Treatment of Celiac Disease
4. BioLineRx Announces Receipt of a Notice of Allowance from USPTO for Patent on Use of BL-8020, an Oral, Interferon-Free Treatment for Hepatitis C
5. BioLineRx To Present At 15th Annual Rodman & Renshaw Global Investment Conference In New York
6. BioLineRx Announces Issuance of United States Patent Covering Use of BL-8040 for Obtaining Stem Cells
7. BioLineRx to Present at 15th International Celiac Disease Symposium
8. BioLineRx to Present at 2013 Stifel Nicolaus Healthcare Conference In Boston
9. BioLineRx Appoints B. J. Bormann to Board of Directors
10. BioLineRx Reports Second Quarter 2013 Results
11. BioLineRx Announces Publication of Positive Pre-Clinical Results for BL-8040 in Treatment of Thrombocytopenia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... 2017  Genesis Healthcare Services has merged with Hospice ... by Bill Monast , President and CEO of ... Nathan Feltman , executives with Home Health Depot, Inc., ... This acquisition helps Hospice Cloud maintain its ... durable medical equipment (DME) solutions for the hospice industry. ...
(Date:2/23/2017)... 2017 Nevro Corp. (NYSE: NVRO), a global medical ... treatment of chronic pain, today reported financial results for the ... 2016 Accomplishment & Highlights: Achieved ... increase of 228% as reported, over the prior year ... of 612% over the prior year International ...
(Date:2/23/2017)... 23, 2017 Research and Markets has announced ... - 2016" report to their offering. ... The latest research Fibromyalgia Drugs Price ... in the global Fibromyalgia market. The research answers the ... marketed for Fibromyalgia and their clinical attributes? How are they positioned ...
Breaking Medicine Technology:
(Date:2/24/2017)... ... February 24, 2017 , ... Indiana Fiber Network (IFN) President and CEO ... year. Dyer started as the Chairman of the Management Committee when IFN was ... corporation including the recruitment of investor/owners and development of the business plan. He ...
(Date:2/24/2017)... CA (PRWEB) , ... February 24, 2017 , ... ... for qualifying into the Senior International Elite division on February 12th. Ms. ... Around divisions at the elite qualifier competition held in Las Vegas, Nevada. Frida ...
(Date:2/23/2017)... ... February 23, 2017 , ... On February ... a letter to withdraw previous guidance issued by the Obama Administration ... guidance issued in May 2016 by the Obama Administration came in response to ...
(Date:2/23/2017)... NJ (PRWEB) , ... February 23, 2017 , ... ... media outlet with a clinician-based audience, will be participating in Rare Disease Day ... in Washington, D.C. In addition, Rare Disease Report, a website, weekly e-newsletter and ...
(Date:2/23/2017)... ... , ... Hamlin Dental Group and Dr. Hamid Reza, dentist in North ... month of February, patients who visit Hamlin Dental Group will receive a ticket for ... at the Cheesecake Factory. , Tickets are available for routine dental visits and ...
Breaking Medicine News(10 mins):